Phase 3 Clinical Trials With Primary Completion Dates in April 2020

This is a list of Phase 3 trials with primary completion dates in April 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
CBDYTarget Group Inc.2020-04-01Phase 3NCT03180307OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
CHHLChina Holdings, Inc.2020-04-01Phase 3NCT02971345Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
DCTHDelcath Systems, Inc.2020-04-01Phase 3NCT02678572Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
IMMUImmunomedics, Inc.2020-04-01Phase 3NCT02574455ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer
INOInovio Pharmaceuticals, Inc.2020-04-01Phase 3NCT03185013REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
NERVMinerva Neurosciences, Inc.2020-04-01Phase 3NCT03397134Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
OPHLYOno Pharmaceutical Co., Ltd.2020-04-01Phase 3NCT03117049Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)